FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2727832032> ?p ?o ?g. }

• W2727832032 endingPage "1814" @default.
• W2727832032 startingPage "1791" @default.
• W2727832032 abstract "Exenatide once weekly (ExeOW, Bydureon®, Astra Zeneca), a drug belonging to the class of glucagon-like peptide-1 (GLP-1) receptor agonists, is the first agent approved for treatment of type 2 diabetes (T2D) that can be administered on a weekly basis.Data concerning treatment of T2D with ExeOW are reviewed with special reference to its long-term efficacy, tolerability, and safety. Relevant literature was identified through the PubMed database from inception to January 2015.In randomized clinical trials ExeOW, as add-on to oral antidiabetics, achieved significantly improved glycemic control compared to maximum recommended doses of exenatide twice daily, sitagliptin, pioglitazone, and insulin glargine, as measured by HbA1c. In drug-naïve patients ExeOW was superior to sitagliptin and non-inferior to metformin, whereas non-inferiority to pioglitazone and liraglutide was not proven. In different trials reductions in HbA1c ranged from -1.1% to -2.0%. ExeOW therapy over 6 months was also associated with a mean weight loss of -2 to -4 kg, improved systolic blood pressure and lipid profile, and no hypoglycemia unless associated to sulfonylurea. ExeOW long-term therapy up to 3-6 years allowed persistent glycemic control (HbA1c -1.6%), sustained decreases in blood pressure (-2 mmHg), and improvements of lipid profile. ExeOW tolerability was comparable to that of the other GLP-1 receptor agonists, with better gastrointestinal tolerability when direct comparison was done (namely liraglutide and exenatide BID), but higher incidence of injection site reactions and few treatment discontinuations mainly due to gastrointestinal events.ExeOW is a well-tolerated and convenient option for long-term treatment of T2D allowing significant and persistent glycemic control with moderate weight loss and low risk of hypoglycemia unless associated with sulfonylureas." @default.
• W2727832032 created "2017-07-14" @default.
• W2727832032 creator A5049715149 @default.
• W2727832032 creator A5059685674 @default.
• W2727832032 creator A5086369928 @default.
• W2727832032 date "2017-07-03" @default.
• W2727832032 modified "2023-10-06" @default.
• W2727832032 title "A Review of the Long-Term Efficacy, Tolerability, and Safety of Exenatide Once Weekly for Type 2 Diabetes" @default.
• W2727832032 cites W1563830789 @default.
• W2727832032 cites W1565699562 @default.
• W2727832032 cites W1597439261 @default.
• W2727832032 cites W1898466139 @default.
• W2727832032 cites W1944521216 @default.
• W2727832032 cites W1965072462 @default.
• W2727832032 cites W1969754897 @default.
• W2727832032 cites W1976838333 @default.
• W2727832032 cites W1980022623 @default.
• W2727832032 cites W1981012218 @default.
• W2727832032 cites W1983616459 @default.
• W2727832032 cites W1984177371 @default.
• W2727832032 cites W1987407806 @default.
• W2727832032 cites W1989713397 @default.
• W2727832032 cites W1996638018 @default.
• W2727832032 cites W2003893064 @default.
• W2727832032 cites W2004409542 @default.
• W2727832032 cites W2004977380 @default.
• W2727832032 cites W2008132861 @default.
• W2727832032 cites W2008173728 @default.
• W2727832032 cites W2009288620 @default.
• W2727832032 cites W2010033044 @default.
• W2727832032 cites W2010976066 @default.
• W2727832032 cites W2017810555 @default.
• W2727832032 cites W2018940614 @default.
• W2727832032 cites W2029071587 @default.
• W2727832032 cites W2030757778 @default.
• W2727832032 cites W2033831627 @default.
• W2727832032 cites W2043900831 @default.
• W2727832032 cites W2044374397 @default.
• W2727832032 cites W2054925541 @default.
• W2727832032 cites W2057002261 @default.
• W2727832032 cites W2057410639 @default.
• W2727832032 cites W2057913111 @default.
• W2727832032 cites W2059678666 @default.
• W2727832032 cites W2063400466 @default.
• W2727832032 cites W2065319712 @default.
• W2727832032 cites W2066987382 @default.
• W2727832032 cites W2072691447 @default.
• W2727832032 cites W2083357334 @default.
• W2727832032 cites W2086177834 @default.
• W2727832032 cites W2089938750 @default.
• W2727832032 cites W2092361523 @default.
• W2727832032 cites W2093104618 @default.
• W2727832032 cites W2099352903 @default.
• W2727832032 cites W2104818363 @default.
• W2727832032 cites W2106036385 @default.
• W2727832032 cites W2107949845 @default.
• W2727832032 cites W2110725041 @default.
• W2727832032 cites W2120886606 @default.
• W2727832032 cites W2122643907 @default.
• W2727832032 cites W2122696108 @default.
• W2727832032 cites W2129934471 @default.
• W2727832032 cites W2130478319 @default.
• W2727832032 cites W2130684080 @default.
• W2727832032 cites W2133617810 @default.
• W2727832032 cites W2136546775 @default.
• W2727832032 cites W2138077952 @default.
• W2727832032 cites W2139485303 @default.
• W2727832032 cites W2139925874 @default.
• W2727832032 cites W2140367917 @default.
• W2727832032 cites W2150614212 @default.
• W2727832032 cites W2152984355 @default.
• W2727832032 cites W2159198773 @default.
• W2727832032 cites W2160088494 @default.
• W2727832032 cites W2164416879 @default.
• W2727832032 cites W2164535707 @default.
• W2727832032 cites W2165465852 @default.
• W2727832032 cites W2167984392 @default.
• W2727832032 cites W2172193326 @default.
• W2727832032 cites W2198799924 @default.
• W2727832032 cites W2519803668 @default.
• W2727832032 cites W2520371120 @default.
• W2727832032 cites W4230892627 @default.
• W2727832032 doi "https://doi.org/10.1007/s12325-017-0499-6" @default.
• W2727832032 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5565650" @default.
• W2727832032 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28674957" @default.
• W2727832032 hasPublicationYear "2017" @default.
• W2727832032 type Work @default.
• W2727832032 sameAs 2727832032 @default.
• W2727832032 citedByCount "21" @default.
• W2727832032 countsByYear W27278320322017 @default.
• W2727832032 countsByYear W27278320322018 @default.
• W2727832032 countsByYear W27278320322019 @default.
• W2727832032 countsByYear W27278320322020 @default.
• W2727832032 countsByYear W27278320322021 @default.
• W2727832032 countsByYear W27278320322022 @default.
• W2727832032 crossrefType "journal-article" @default.
• W2727832032 hasAuthorship W2727832032A5049715149 @default.
• W2727832032 hasAuthorship W2727832032A5059685674 @default.

• next